Emulate Stock
Organs-on-Chips Company
Sign up today and learn more about Emulate Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Emulate Stock
Emulate develops Organs-on-Chips technologies through an automated human bioemulation platform that aims to mimic true human physiology so that responses to medicines, chemicals, and diseases can be accurately predicted. Through co-innovation with collaborators and internal programs, Emulate aims to advance product innovation, design, and safety across a range of applications in drug development, personalized medicine, agriculture, and chemical-based consumer products.
Emulate was founded in 2013 and is based in Bostom, MA. Notable investors in Emulate include Founders Fund, Glass Wall Syndicate, and Starlight Ventures.
Investors
Founders Fund
Lyft, Spotify, Airbnb, Stripe, Flexport, Palantir Technologies, Wish, Compass, Zenefits, Eat Just
Northpond Ventures
ALS Finding a Cure
SciFi VC
Zymergen, PsiQuantum, Anchorage Digital, Synthego, Virta Health, Emulate
National Institutes of Health
Funding History
July 2014 | $12.0M |
---|---|
March 2016 | $45.0M |
June 2018 | $36.0M |
August 2019 | $28.2M |
August 2021 | $20.7M |
August 2021 | $60.4M |
Management
Chief Executive Officer
Jim Corbett
Chief Financial Officer
Scott Kantor
Press
marketwatch - Jan, 5 2023
EMulate Therapeutics Plans 2.5M Share IPOow - Dec, 10 2022
Emulate Shares Positive Data on Key Liver Chip Tox Studybioworld - Sep, 22 2022
Emulate launches new AAV transduction application for Liver-Chipbiospace - Nov, 17 2021
EMulate Therapeutics Announces the Incorporation of Two Wholly Owned Subsidiariesfinsmes - Sep, 8 2021
Emulate Raises $82M in Series E Funding